0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Orphan drugs and the NHS: should we value rarity?

      BMJ : British Medical Journal

      Cost-Benefit Analysis, Drug Costs, Health Status, Humans, Orphan Drug Production, economics, Rare Diseases, drug therapy, State Medicine, Treatment Outcome

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Author and article information

          Journal
          16254305
          1273462
          10.1136/bmj.331.7523.1016

          Comments

          Comment on this article